Novel Kinase Inhibitor Shows Efficacy in Patients with Advanced HCC Tumors Overexpressing AFP
LY2157299 monohydrate showed promising efficacy results in patients with advanced HCC tumors overexpressing AFP.
LY2157299 monohydrate showed promising efficacy results in patients with advanced HCC tumors overexpressing AFP.
Circulating tumor cells are a useful adjunct in the diagnosis of pancreatic ductal adenocarcinoma.
PET/CT may prevent unnecessary laparotomy by detecting occult metastatic disease in patients with resectable/borderline pancreatic cancer.
Nab-paclitaxel plus gemcitabine sustained overall survival rates compared with gemcitabine alone in patients with metastatic pancreatic adenocarcinoma.
Cetuximab should not be added to first-line FOLFOX4 for patients whose mCRC harbors RAS mutations.
Cetuximab does not improve overall survival or clinical complete response rates for esophageal cancer chemoradiation.
Early detection of high-risk, presymptomatic gastric cancer with endoscopic screening is associated with improved survival.
Data indicate that everolimus did not improve overall survival in patients with advanced HCC following sorafenib failure.
Second-line treatment with paclitaxel/trastuzumab showed promising activity in trastuzumab-naïve patients with HER2-positive gastric cancer.
Patients with stage IV gastric tumors positive for MET protein expression have poorer survival than those without MET expression.